These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Design and biological evaluation of imidazo[1,2-a]pyridines as novel and potent ASK1 inhibitors. Terao Y; Suzuki H; Yoshikawa M; Yashiro H; Takekawa S; Fujitani Y; Okada K; Inoue Y; Yamamoto Y; Nakagawa H; Yao S; Kawamoto T; Uchikawa O Bioorg Med Chem Lett; 2012 Dec; 22(24):7326-9. PubMed ID: 23147077 [TBL] [Abstract][Full Text] [Related]
7. Design, synthesis, and evaluation of novel VEGFR2 kinase inhibitors: discovery of [1,2,4]triazolo[1,5-a]pyridine derivatives with slow dissociation kinetics. Oguro Y; Cary DR; Miyamoto N; Tawada M; Iwata H; Miki H; Hori A; Imamura S Bioorg Med Chem; 2013 Aug; 21(15):4714-29. PubMed ID: 23755884 [TBL] [Abstract][Full Text] [Related]
8. Design, Synthesis, and Biological Evaluation of 1-Benzyl-1H-pyrazole Derivatives as Receptor Interacting Protein 1 Kinase Inhibitors. Zou C; Xiong Y; Huang LY; Song CL; Wu XA; Li LL; Yang SY Chem Biol Drug Des; 2016 Apr; 87(4):569-74. PubMed ID: 26577270 [TBL] [Abstract][Full Text] [Related]
9. Structure-based design, synthesis, and evaluation of 4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine derivatives as novel c-Met inhibitors. Zhang L; Zhang B; Zhao J; Zhi Y; Wang L; Lu T; Chen Y Eur J Med Chem; 2017 Sep; 138():942-951. PubMed ID: 28755635 [TBL] [Abstract][Full Text] [Related]
10. Discovery of a Potent, Selective, Orally Bioavailable, and Efficacious Novel 2-(Pyrazol-4-ylamino)-pyrimidine Inhibitor of the Insulin-like Growth Factor-1 Receptor (IGF-1R). Degorce SL; Boyd S; Curwen JO; Ducray R; Halsall CT; Jones CD; Lach F; Lenz EM; Pass M; Pass S; Trigwell C J Med Chem; 2016 May; 59(10):4859-66. PubMed ID: 27078757 [TBL] [Abstract][Full Text] [Related]
11. Cytosolic calcium mediates RIP1/RIP3 complex-dependent necroptosis through JNK activation and mitochondrial ROS production in human colon cancer cells. Sun W; Wu X; Gao H; Yu J; Zhao W; Lu JJ; Wang J; Du G; Chen X Free Radic Biol Med; 2017 Jul; 108():433-444. PubMed ID: 28414098 [TBL] [Abstract][Full Text] [Related]
12. Mechanistic understanding of translational pharmacokinetic-pharmacodynamic relationships in nonclinical tumor models: a case study of orally available novel inhibitors of anaplastic lymphoma kinase. Yamazaki S; Lam JL; Zou HY; Wang H; Smeal T; Vicini P Drug Metab Dispos; 2015 Jan; 43(1):54-62. PubMed ID: 25349124 [TBL] [Abstract][Full Text] [Related]
13. Discovery of novel pyrrolo-pyridine/pyrimidine derivatives bearing pyridazinone moiety as c-Met kinase inhibitors. Wang LX; Liu X; Xu S; Tang Q; Duan Y; Xiao Z; Zhi J; Jiang L; Zheng P; Zhu W Eur J Med Chem; 2017 Dec; 141():538-551. PubMed ID: 29107421 [TBL] [Abstract][Full Text] [Related]
14. Structure-based optimization of pyrazolo-pyrimidine and -pyridine inhibitors of PI3-kinase. Staben ST; Heffron TP; Sutherlin DP; Bhat SR; Castanedo GM; Chuckowree IS; Dotson J; Folkes AJ; Friedman LS; Lee L; Lesnick J; Lewis C; Murray JM; Nonomiya J; Olivero AG; Plise E; Pang J; Prior WW; Salphati L; Rouge L; Sampath D; Tsui V; Wan NC; Wang S; Weismann C; Wu P; Zhu BY Bioorg Med Chem Lett; 2010 Oct; 20(20):6048-51. PubMed ID: 20822905 [TBL] [Abstract][Full Text] [Related]
15. Discovery of novel imidazo[1,2-a]pyridines as inhibitors of the insulin-like growth factor-1 receptor tyrosine kinase. Ducray R; Simpson I; Jung FH; Nissink JW; Kenny PW; Fitzek M; Walker GE; Ward LT; Hudson K Bioorg Med Chem Lett; 2011 Aug; 21(16):4698-701. PubMed ID: 21775140 [TBL] [Abstract][Full Text] [Related]
16. Synthesis, Docking Study and Kinase Inhibitory Activity of a Number of New Substituted Pyrazolo[3,4-c]pyridines. Sklepari M; Lougiakis N; Papastathopoulos A; Pouli N; Marakos P; Myrianthopoulos V; Robert T; Bach S; Mikros E; Ruchaud S Chem Pharm Bull (Tokyo); 2017; 65(1):66-81. PubMed ID: 28049917 [TBL] [Abstract][Full Text] [Related]
17. Design, synthesis and biological evaluation of 1H-pyrrolo[2,3-b]pyridine and 1H-pyrazolo[3,4-b]pyridine derivatives as c-Met inhibitors. Liu N; Wang Y; Huang G; Ji C; Fan W; Li H; Cheng Y; Tian H Bioorg Chem; 2016 Apr; 65():146-58. PubMed ID: 26950400 [TBL] [Abstract][Full Text] [Related]
18. Design, Synthesis, and Structure-Activity Relationships of Pyridine-Based Rho Kinase (ROCK) Inhibitors. Green J; Cao J; Bandarage UK; Gao H; Court J; Marhefka C; Jacobs M; Taslimi P; Newsome D; Nakayama T; Shah S; Rodems S J Med Chem; 2015 Jun; 58(12):5028-37. PubMed ID: 26039570 [TBL] [Abstract][Full Text] [Related]
19. Structure-based design and synthesis of imidazo[1,2-a]pyridine derivatives as novel and potent Nek2 inhibitors with in vitro and in vivo antitumor activities. Xi JB; Fang YF; Frett B; Zhu ML; Zhu T; Kong YN; Guan FJ; Zhao Y; Zhang XW; Li HY; Ma ML; Hu W Eur J Med Chem; 2017 Jan; 126():1083-1106. PubMed ID: 28039836 [TBL] [Abstract][Full Text] [Related]
20. Synthesis and biological evaluation of imidazo[1,2-a]pyridine derivatives as novel PI3 kinase p110alpha inhibitors. Hayakawa M; Kaizawa H; Kawaguchi K; Ishikawa N; Koizumi T; Ohishi T; Yamano M; Okada M; Ohta M; Tsukamoto S; Raynaud FI; Waterfield MD; Parker P; Workman P Bioorg Med Chem; 2007 Jan; 15(1):403-12. PubMed ID: 17049248 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]